That's a global assessment of looking at what are deemed to be good value for money investments to stem or address the problem of antimicrobial resistance. You need to put that in perspective. Number one, about $8 trillion to $9 trillion per year is spent on health globally. This study was covering a period through to 2050. When you look at the total amount spent on just health alone over that period of time, that's a very, very large number. This is a fraction of the total cost in health.
The investment set of interventions relates to specific things in the health care sector related to good surveillance, more judicious procurement of good-quality medicines, the training of clinicians in prescription practices, and things like that. In terms of the package of interventions that were costed up, most health care systems are doing those interventions to one degree or another. The problem is that we're not doing them universally at scale, so the coverage is very patchy. You may have a centre of excellence in Hamilton, Ontario, that's doing everything right in the McMaster health care system, whereas you may find that over in Stoney Creek or Burlington there's no compliance or consistency with those measures.